Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In diagnosing systemic lupus erythematosus (SLE), it is necessary to differentiate it from drug-induced lupus erythematosus (DILE). Herein, we report a case of a patient who developed class V lupus nephritis (LN) while taking ethosuximide (ESM), making it difficult to distinguish between ESM-induced DILE and SLE.
Case: A 12-year-old boy who had been taking ESM for absence epilepsy for the past three years. One month prior, he was diagnosed with severe proteinuria and hematuria. As these symptoms did not improve, a detailed examination, including a renal biopsy, was performed. There were no extrarenal SLE symptoms. Blood tests showed an antinuclear antibody titer of 1:80, negative for both anti-dsDNA and anti-Sm antibodies, anti-cardiolipin antibody (aCL) 48.3 U/mL, low complement levels, normal eGFR, and did not meet the diagnostic criteria for SLE. DILE due to ESM could not be ruled out; therefore, a renal biopsy was performed. Biopsy revealed diffuse spike formation and subepithelial deposits in the glomerular capillary walls, leading to a diagnosis of class V LN. As SLE, remission induction therapy with steroid pulse treatment was initiated in the first week of hospitalization. Prednisolone (PSL) was administered from the second week, and maintenance therapy with mycophenolate mofetil (MMF) and hydroxychloroquine (HCQ) was added from the fourth week. After three months, the urinalysis findings normalized, and no extra-renal SLE symptoms developed. At 15 months, a repeat renal biopsy was performed for evaluation; no active lesions were present, but features of class V LN remained. At 18 months, complement levels normalized, and all autoantibodies were negative; therefore, PSL was discontinued. MMF and HCQ were continued, and normal urinalysis results were maintained.
There are no clear diagnostic criteria for DILE, and differentiation based on serum biomarkers alone is difficult. In this case, the absence of extrarenal symptoms and the presence of a drug taken for a certain period made the diagnosis more challenging. Prompt diagnosis and treatment of SLE are essential to minimize complications. Furthermore, the presence of nephrotic-range proteinuria is an indication for renal biopsy, which led to the diagnosis of class V LN in this case. Even when it is difficult to distinguish between DILE and SLE, if there is significant proteinuria, the possibility of LN should be considered, and prompt evaluation, including renal biopsy, should be performed.
